Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).
Launay-Vacher
Vincent
V
ICAR, Department of Nephrology, Hôpital Pitié-Salpêtrière, 83 boulevard de l'Hôpital, 75013 Paris, France. vincent.launay-vacher@psl.aphp.fr
Rey
Jean-Baptiste
JB
Isnard-Bagnis
Corinne
C
Deray
Gilbert
G
Daouphars
Mikael
M
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy
D000970:Antineoplastic Agents; D002945:Cisplatin